
SONO 2026: Beth Sandy Ties NSCLC Treatment Updates to Nursing Toxicity Care
Beth Sandy, MSN, CRNP, FAPO, reviewed ADCs, immunotherapy, and targeted therapy in NSCLC with a focus on what nurses should monitor.
Antibody-drug conjugates (ADCs), immunotherapy, and targeted therapies continue to reshape care for patients with non–small cell lung cancer (NSCLC), and each class brings toxicities that oncology nurses must recognize and manage, according to Beth Sandy, MSN, CRNP, FAPO, who presented an NSCLC update at the 10th Annual School of Nursing Oncology (SONO), held November 11, 2026, at the New York Hilton Midtown in New York City.2
Sandy, a nurse practitioner in thoracic oncology at the Abramson Cancer Center, University of Pennsylvania, in Philadelphia,1,2 also served on the planning committee for this year's meeting. Her session, "Evolving Standards in NSCLC: Immunotherapy, ADCs, and Molecular Testing," was 1 of a series of 25-minute disease updates delivered to nurses and advanced practice providers.2
What did the NSCLC session cover?
In an on-site interview with Oncology Nursing News, Sandy described a talk built around the major drug classes now used in the disease.
"We talked about antibody-drug conjugates, immunotherapy, and targeted therapies, mainly in non–small cell lung cancer," Sandy said. "It was a 25-minute update, and we really talked a lot also about how that relates to nursing care of patients, particularly toxicity management and what to look for and what to monitor for."
That emphasis reflects the practical demands of NSCLC care, in which nurses are often responsible for patient education, symptom monitoring, and early recognition of adverse events across oral targeted agents, infused immunotherapy, and ADCs. Sandy has addressed those demands in prior Oncology Nursing News coverage, including a September 2026 discussion of
Why is SONO designed for oncology nurses?
Sandy said the meeting's format, which pairs brief updates with national experts across disease areas, is intended to fit the broad scope of everyday oncology nursing practice.
"This is a great conference for nurses to attend. You'll get basically 25-minute brief updates on all different kinds of diseases, solid tumors, hematologic malignancies, and then also things like oncologic emergencies," she said.
She noted that audience participation is built into the program. "The quality of the speakers has been great so far. It's just been lively and entertaining. You can send your questions in and we will answer them right there on the spot at the Q&A session," Sandy said. "So it's a great conference. It's our 10th year. It's been really successful in different places throughout the country, and we're having a great time here in New York."
How does the meeting's timing help nurses keep up with new data?
Held late in the year, SONO follows several of the major oncology meetings where practice-informing data are presented. "This conference is well placed," Sandy said, noting that it follows the European Society for Medical Oncology (ESMO) Congress and the World Conference on Lung Cancer, as well as the ASCO Annual Meeting in the summer. "So we can really give all of our updates here."
SONO is also held alongside the 44th Annual Chemotherapy Foundation Symposium (CFS), which ran November 11 to 13, 2026, at the same venue.4
"The other great thing about SONO is it's piggybacked right onto Chemo Foundation Symposium. So your conference registration will cover you to go to Chemo Foundation Symposium as well," Sandy said. "So you can get several days, lots of CEs, and lots of updates both from nursing and then from the physician conference as well."
What are the key takeaways for oncology nurses?
- ADCs, immunotherapy, and targeted therapies each carry distinct toxicity profiles in NSCLC, so monitoring plans should be tailored to the drug class a patient receives.
- Toxicity management, including knowing what to look for and what to monitor for, remains a central nursing responsibility as NSCLC treatment options expand.
- Year-end meetings such as SONO consolidate data presented earlier at ESMO, the World Conference on Lung Cancer, and ASCO into brief, nurse-focused updates.
References
1. Beth Sandy, CRNP. Penn Medicine. Accessed November 13, 2026.
2. 10th Annual School of Nursing Oncology (SONO): agenda. Physicians' Education Resource. Accessed November 13, 2026.
3. Sandy B. FDA approves frontline sevabertinib for HER2-mutant advanced NSCLC patients. Oncology Nursing News. September 12, 2026. Accessed November 13, 2026.
4. 44th Annual Chemotherapy Foundation Symposium (CFS): Innovative Cancer Therapy for Tomorrow. Physicians' Education Resource. Accessed November 13, 2026.
Related to this article








